Germany · Delayed Price · Currency is EUR Medios AG Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 10.4% to EUR 2.1 billion with EBITDA pre up 17.8% and net profit up 22.4%. 2026 guidance targets up to 2% revenue growth and up to 9.6% EBITDA pre growth, with focus on profitability and cash flow. Share buybacks and disciplined capital allocation remain priorities.
-
Record revenue and EBITDA pre growth were achieved, driven by both organic and inorganic expansion, with strong cash flow and margin improvements. Guidance for 2025 is confirmed, with continued focus on advanced therapies and further international growth.
-
Revenue grew 9.3% to EUR 992 million and EBITDA pre rose 48.8% to EUR 46.3 million, with margin expansion across all segments. Guidance for 2025 is confirmed, targeting EUR 2 billion revenue and EUR 96 million EBITDA pre, while strategic initiatives and international expansion continue.
-
Q1 2025 saw strong revenue and EBITDA growth, driven by international business and Ceban integration, with improved margins and confirmed full-year guidance. Executive transitions and new incentive plans were announced, supporting future growth and operational focus.
Fiscal Year 2024
-
Record Q3 and strong nine-month results driven by Ceban integration and margin focus, with revenue up 4% and EBITDA pre up over 20%. Guidance for 2024 is confirmed, with continued expansion in Europe and advanced therapies planned.
-
Revenue grew 6% to EUR 907 million in H1 2024, with EBITDA pre up 7% and strong cash flow. The Ceban acquisition was completed and integrated, boosting international presence and margins. 2024 guidance is confirmed, with continued focus on specialty pharma and advanced therapies.